INTERNATIONAL ENCYCLOPEDIA OF PHARMACOLOGY AND THERAPEUTICS

Section 111

VIRAL CHEMOTHERAPY Volume 1

SECTION EDITOR

D. SHUGAR

Section 111

VIRAL CHEMOTHERAPY

Volume 1

SECTION EDITOR

D. SHUGAR

Polish Academy of Sciences Warsaw, Poland





PERGAMON PRESS

U.K.

Pergamon Press Ltd., Headington Hill Hall, Oxford OX3 0BW, England

U.S.A.

Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, New York 10523, U.S.A.

CANADA

Pergamon Press Canada Ltd., Suite 104,

150 Consumers Road, Willowdale, Ontario M2J 1P9, Canada

AUSTRALIA

Pergamon Press (Aust.) Pty. Ltd., P.O. Box 544,

Potts Point, N.S.W. 2011, Australia

FRANCE

Pergamon Press SARL, 24 rue des Ecoles,

75240 Paris, Cedex 05, France

FEDERAL REPUBLIC OF GERMANY Pergamon Press GmbH, Hammerweg 6,

D-6242 Kronberg-Taunus, Federal Republic of Germany

Copyright © 1984 Pergamon Press Ltd.

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means: electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the publishers.

First edition 1984

Library of Congress Cataloging in Publication Data

Main entry under title:
Viral chemotherapy.
(International encyclopedia of pharmacology and therapeutics; section 3)
"Published as Supplement no. 11 1983, to the review journal Pharmacology & therapeutics"—
Verso t.p., v. 1.
1. Antiviral agents. 2. Virus diseases—
Chemotherapy. 1. Shugar, D. II. Series. [DNLM: 1. Antiviral agents—Pharmacodynamics. 2. Antiviral agents—Therapeutic use. 3. Viruses. 4. Virus diseases—Drug therapy. WV 4 158 section 111]
RM411.V57 1983 616.9'25061 82-24530

British Library Cataloguing in Publication Data

Viral chemotherapy (International encyclopedia of pharmacology and therapeutics; section 111)
Vol. 1
J. Viral chemotherapy
I. Shugar, D. II. Series
615.5'8 RM411
ISBN 0-08-029821-4

Published as Supplement No. 11 (1983) to the review journal *Pharmacology & Therapeutics*

Photo typeset by Macmillan India Ltd., Bangalore
Printed in Great Britain by A. Wheaton & Co. Ltd., Exeter

PREFACE

SINCE viruses are obligate intracellular parasites, fully dependent on the host cells, which furnish the necessary apparatus required for the transformation of the genetic information of the viral nucleic acid into progeny viral particles, considerable scepticism existed up to only a few years ago as to the feasibility of developing antiviral agents sufficiently specific to readily traverse the host cell membrane and to inhibit such processes as viral uncoating, replication and assembly without adversely affecting the normal metabolic functions of the cell.

The early, frequently vociferous and even vituperative, opposition to viral chemotherapy came largely from some of the proponents of immunization. The successes achieved by vaccination are indisputable, and include virtual eradication of smallpox, and effective control of such diseases as poliomyelitis. However, both the development and subsequent production of vaccines are by no means free of problems, some of them rather formidable. The recent FDA approval of a vaccine for hepatitis B, prepared by isolation of hepatitis B surface antigen (HBsAg) from viral particles collected from the blood of human carriers, represents a significant new achievement in this field. But it should not be overlooked that it is "the first completely new viral vaccine in 10 years", while its use is to be limited only to those considered at high risk of developing the disease. Furthermore, development of vaccines against, for example, herpes, influenza and rhino viruses poses even more formidable theoretical and practical problems. One of the new approaches, involving the use of chemically synthesized peptides, and exemplified by the recent report of an effective vaccine against foot-and-mouth disease in guinea pigs and rabbits, holds out considerable promise for further advances, particularly when considered with the possible applications of recombination techniques. Meanwhile, it would appear obvious that chemotherapy offers the only alternative, in those instances where a fully effective vaccine is not already available, and, in those instances where it is by itself sufficiently effective, may be preferable to immunization.

During the past 10 years, scepticism regarding the possibilities of viral chemotherapy have been largely dispelled, in large part by practical demonstrations which have already resulted in official approval, in a number of countries, of several compounds for clinical use. As in the case of many other drugs, initial potential candidates for viral chemotherapy were uncovered during the course of *in vitro* random screening programs, with attempts at subsequent improvements based on structure-activity studies, i.e. evaluations of relative activities and cytotoxicities of various synthetically modified analogues of the parent compound with proven activity. The number of promising new agents is presently increasing at an impressive rate, and an appreciable number of these have attained the stage of being subjected to preclinical trials. One of the impressive recent achievements is the FDA approval for use of Acyclovir (or Acycloguanosine) in treatment of primary genital herpes less than 5 years following the initial report on the discovery of this compound and its *in vitro* activity against herpes viruses types 1 and 2.

Concurrently with the foregoing, remarkable progress has been achieved during the 1970s in the elucidation of the molecular biology of viral replication. This has led to the pinpointing of a variety of 'targets', especially viral-encoded enzymes and proteins, with specificities frequently sufficiently different from the corresponding constituents of the host cells to provide a reasonably solid basis for further, and more fundamental, research in this field. As a result of this, one of the interesting features of a number of new antiviral agents, currently in course of development, has been the success achieved in delineating their

vi Preface

mode(s) of action. It is to be anticipated that this will significantly contribute to the design of more effective compounds. An important result of the foregoing is the gradual introduction of so-called more 'rational' approaches in the search for new, and more effective, agents, which is esthetically more satisfying and stimulating to the organic chemists who participate in the necessary synthetic programs and to the virologists, biochemists, enzymologists, pharmacologists, clinicians (and physical chemists and theoretical chemists involved in structure-activity relationships), all of whose collaborative efforts contribute to the eventual introduction of a useful compound into the clinic. Current progress is now such as to envisage the use of combination therapy, based on employment of two or more agents, each of which may affect a different step in viral replication, a field as yet relatively little explored.

With the foregoing in mind, contributors to this volume and to succeeding ones have been asked to concentrate as much as possible on fundamental aspects of their respective fields, so that these will prove useful in further research, and, wherever possible, to present as much detail as possible regarding the mechanism(s) of action of the agents described. I am indebted to most of the contributors for their assistance in attempts to attain his objective. I am also grateful to friends and colleagues who have been kind enough to offer suggestions and advice as to the nature and scope of the contributions required in such a volume and, particularly, to Dr. Ernest C. Herrmann, Jr., and Dr. William H. Prusoff, both well-known pioneers in the development and application of antiviral agents, and to Dr. Alan Sartorelli and Dr. Barbara Z. Renkin, whose assistance in dealing and processing of contributions has been invaluable.

g cause. Es a che arres con particularly when gones is result the possible of abroadous services of a construction of a

David Shugar
Institute of Biochemistry and Biophysics,
Academy of Sciences; and Department of Biophysics,
University of Warsaw, Warsaw

LIST OF CONTRIBUTORS I am of any of reconstitutions

BLACK, Francis L. Yale University School of Medicine dependents Department of Epidemiology and Public Health New Haven, Connecticut 06510 USA BOCKSTAHLER, Larry E. STATE V UNDARGED BY SE Bureau of Radiological Health Food and Drug Administration to A all and a Rockville, Maryland 20857 and and report USA CARRASCO, Luis Departamento de Microbiología de la UAM Centro de Biología Molecular Canto Blanco, Madrid-34 Spain CHEN, Ming S. Applebrook Research Center Smith Kline Animal Health Products 1600 Paoli Pike Westchester, Pennsylvania 19380 USA COHEN, Seymour S. Department of Pharmacological Sciences State University of New York at Stony Brook Stony Brook, New York 11794 USA COOHILL, Thomas P. Biophysics Program Western Kentucky University Bowling Green, Kentucky 42101 USA Doskočil, Jiři Institute of Molecular Genetics Czechoslovak Academy of Sciences 160000 Prague Czechoslovakia FENNER, Frank John Curtin School of Medical Research The Australian National University Canberra, Australia FISCHER, Paul H. Department of Human Oncology University of Wisconsin Madison, Wisconsin 53706 USA GALBRAITH, Alan Pharmaceuticals Division Ciba-Geigy (UK) Horsham, Sussex England HELLMAN, Kiki B. Bureau of Radiological Health Food and Drug Administration Rockville, Maryland 20857 USA

HERRMANN, Ernest C., Jr.

Peoria, Illinois 60656

USA

Department of Basic Sciences

University of Illinois College of Medicine

Peoria School of Medicine

HERRMANN, Judith A. Department of Basic Sciences
Peoria School of Medicine
University of Illinois College of Medicine Peoria, Illinois 60656 USA LIN, Tai-Shun N, Tai-Shun
Department of Pharmacology Yale University School of Medicine 333 Cedar Street New Haven, Connecticut 06510 USA LYTLE, C. David Bureau of Radiological Health Food and Drug Administration Rockville, Maryland 20857 USA MANCINI, William R. Department of Pharmacology Yale University School of Medicine 333 Cedar Street New Haven, Connecticut 06510 USA NORTH, Thomas W. Department of Biochemistry and Pharmacology Tufts University Schools of Medicine 136 Harrison Avenue Boston, Massachusetts 02111 LISA OTTO, Michael J. Department of Pharmacology Yale University School of Medicine 333 Cedar Street New Haven, Connecticut 06510 USA OXFORD, John S. Division of Virology National Institute for Biological Standards and Holly Hill, London NW3, England PERRIN, D. D. Medical Chemistry Group John Curtin School of Medical Research Australian National University Canberra City, ACT 2600, Australia PRUSOFF, William H. Department of Pharmacology Yale University School of Medicine 333 Cedar Street New Haven, Connecticut 06510 USA RADA, Brëtislav Institute of Virology Slovak Academy of Sciences 817 03 Bratislava Czechoslovakia ROBERTS, Joan E. Fordham University Lincoln Center Campus New York, New York 10023 USA

SCHINAZI, Raymond F.
Department of Pediatrics
Emory University School of Medicine
Atlanta, Georgia
USA

SHIAU, George T.
Department of Chemistry
National Taiwan Normal University
Taipei, Taiwan
SHUGAR, David
University of Warsaw
Institute of Experimental Physics
Department of Biophysics
93 Zwirki & Wigury
02-089 Warszawa
Poland

SMITH, Alan E.
National Institute for Medical Research
Medical Research Council
The Ridgeway Mill Hill
London NW7 1AA
England

STEBBING, N.
AMGen, Inc.
1900 Oak Terrace Lane
Newbury Park, California 91320
USA

STUNZI, H.
Institut de Chimie
Université de Neuchâtel
Avenue de Bellevaux 51
CH-2000 Neuchâtel, Switzerland
WALKER, Jamieson

WALKER, Jamieson
Department of Pharmacology
University of Edinburgh
Edinburgh, Scotland

WERNER, Georges H.
Centre de Recherches de Vitry
13, quai Jules Guesde

B.P. 14 F-94400 Vitry-sur-Seine, France Zerial, Aurelio Centre de Recherches de Vitry 13, quai Jules Guesde

B.P. 14 F-94400 Vitry-sur-Seine, France

4.3. Relative roles at different types of infection

LIST	r of contributors	xi
1.	THE NATURE AND CLASSIFICATION OF VIRUSES OF MAN F. Fenner, The Australian National University, Canberra, Australia	1
	1.1. Introductory remarks	55/
	1.2. Introduction	1.0
	1.3. The nature of viruses several factors of several and only and in Stores in the viruses.	\$14. 2
	1.4. The chemical composition of animal viruses and land animal AVICE	8.8. 2
	1.5. The structure of animal viruses	26 5
	1.6. Classification of viruses and discourse golden many to possessing	8.8
	1.7. Short descriptions of the major groups of DNA viruses of vertebra	
	1.8. Short descriptions of the major groups of RNA viruses of vertebra 1.9. Unclassified viruses	
	DENERGRAM VIKUS VCTIVITY OF WISHIGHING	MA .
2.	THE PATHOGENESIS AND FREQUENCY OF VIRAL INFECTION	NS 27
	F. Fenner, The Australian National University, Canberra, Australia	-170
	2.1. Introductory remarks	27
	2.2. Introduction	27
	2.3. Viral infections of the respiratory tract	29
	2.4. Viral infections of the alimentary tract	33
	2.5. Viral infections of the skin which are the process of the skin which are the skin wh	34
	2.6. Genital and genito-urinary infections that a lovery a herivitae.	35
	2.7. Conjunctivitis being the analysis as an array of substitute is a self-inferior	35
	2.8. The systemic spread of viruses	0.0. 36
	2.9 Immunonathology 3.3 Saffana to a list is aboth	40
	2.10. Immunodepression by viruses	41
	2.11 Non-immunological resistance	42
	2.12. Recovery from viral infection is they saths make the same transfer	43
	2.13 Persistent infections 2000 000 000 000 000 000 000 000 000 0	45
	2.14. The significance of the incubation period and the significance of the significance	49
	Annyiral effect of americance in artifal egicles	
3.	DIAGNOSIS OF VIRAL DISEASE AND THE ADVENT OF AN'	
	VIRAL DRUGS research below received and the determinance of the second states of the second s	51
	E. C. HERRMANN, Jr. and Judith A. HERRMANN, University of Illinois of	ınd
	Mobilab, Inc., USA and a streams to vgolookor ban gradoohartsal?	
	3.1. Introduction above a to a ground little surfive as about a realife of	51
	3.2. The present	52
	3.3. The future out of hand a monophism when the chapter mature of the	61
	3.4. Viral diseases of the upper respiratory tract and oral cavity	67
	3.5. Virus diseases of the lower respiratory tract and cardiovascular syste	ms 70
	3.6. Viral diseases of the nervous system and eye	
	3.7. Virus diseases of the skin	79
	3.8. Viral diseases of the urogenital system, the neonate and the newbo	orn 80
	3.9. Viral diseases of the gastrointestinal system	83
	3.10. Conclusions	0.0

4.	THE RELATIVE ROLES OF VACCINES AND DRUGS IN	
	PREVENTION AND TREATMENT OF HUMAN VIRUS DISEASES	93
	F. L. Black, Yale University School of Medicine; USA	
	Introduction	93
	4.1. Antiviral immunizing agents	94
		100
	4.2. Relative roles at different stages of infection	
	4.3. Relative roles in different types of infection	103
	4.4. Summary	105
	I OF CONTRIBUTORS	
5.	THE REPLICATION OF ANIMAL VIRUSES TO THE ABUTTAN THE	1111
	L. CARRASCO, Centro de Biologia Molecular, Madrid, Spain, and A. E. SMITH,	
	Medical Research Council, London, England	
	5.1. Introduction	111.
	5.2. Steps in the viral life-cycle, potential targets for antiviral chemotherapy	112
	5.3. DNA containing viruses of the land of the moliticage of the interest and the land of	115
	5.4. RNA containing viruses against (small), and the set of the state	124
	5.5. Interference of viral development with host metabolism (softizer to all	141
	5.6. Membrane changes produced by viral infection	148
	and the contraction of the contract of the second s	
6.	ANTI-INFLUENZA VIRUS ACTIVITY OF AMANTADINE: A	
	SELECTIVE REVIEW OF LABORATORY AND CLINICAL DATA	169
	J. S. Oxford, Institute for Biological Standards and Control, London, England,	10)
	and A. Galbraith, Pharmaceuticals Division, Ciba-Geigy (UK), Horsham,	
	Sussex granuborus 17	
	6.1. Introduction	170
	6.2. Recent concepts of the molecular biology of influenza virus replication,	
	and application to the development of a strategy for virus control	172
	6.3. Early searches for an influenza virus inhibitor	178
	6.4. Antiviral activity of amantadine in tissue culture	179
	6.5. Inhibition of influenza virus haemagglutinin production	183
	6.6. Genetic and biological variability of influenza viruses	184
	6.7. Mode of action of amantadine	184
	VARIOUS SUBSTITUTION AND A SUBST	104
	6.8. Tissue culture studies of the antiviral effects of combined amantadine	
	and interferon or ribavirin	187
	6.9. Derivatives of amantadine with antiviral activity	188
	6.10. Synthesis of adamantane spiro compounds	188
	6.11. Water-soluble polymers	190
	6.12. Antiviral effect of amantadine in animal models	190
	6.13. Selection of amantadine resistant influenza viruses in the laboratory	193
	6.14. Recombination between drug-resistant and drug-sensitive influenza	1,0
		194
	viruses and toxical and toxical and amountains	
	6.15. Pharmacology and toxicology of amantadine	195
	6.16. Other influenza virus inhibitory compounds	202
	6.17. Influenza vaccines	202
	6.18. Economic aspects of mass vaccination or chemoprophylaxis	
	programmes the state of the sta	203
	6.19. Recurrence of H1N1 viruses as epidemic viruses	. 205
	6.20. Clinical studies with amantadine	205
	Appendix (mid-sit-sit-sit-sit-sit-sit-sit-sit-sit-sit	239
		253
	Summary and conclusions Harva La Hagorif and Tax Adams Harva 81	233
	3.9. Viral descrites of the gastgoinest had system	
	3 D. Concinsion	

Contents

7.	ANTIVIRAL ACTIONS OF METAL IONS AND METAL-CHELATING AGENTS	255
	D. D. Perrin, Australian National University, Canberra, Australia, and H. Stunzi, Université de Neuchâtel, Switzerland	
	7.1. Introduction	255
	7.2. Metal ions in biological systems	257
	7.3. Host-virus interaction	264
		268
	7.4. Application of metal ions and chelating agents in virus control	290
	7.5. Liposomes: a possible new type of delivery agent	293
	7.6. Abbreviations	5
8.	ARANUCLEOSIDES AND ARANUCLEOTIDES IN VIRAL CHEMOTHERAPY	303
	T. W. North, Tufts University Schools of Medicine, Boston, USA, and S. S. Cohen, State University of New York at Stony Brook, USA	202
	8.1. Introduction	303
	8.2. AraC	306
	8.3. AraA	313
	8.4. AraHx	325
	8.5. AraT	325
	8.6. AraG	326
	8.7. AraU	326
	8.8. Other aranucleosides and aranucleoside analogs'	327
	8.9. Summary and conclusions	330
	SIDES: 5-IODQ-2'-DEOXYURIDINE; 5-IODO-2'-DEOXYCYTIDINE; 5-IODO-5'-AMINO-2',5'-DIDEOXYURIDINE W. H. Prusoff, M. S. Chen, P. H. Fischer, T-S. Lin, W. R. Mancini, M. J. Otto, G. T. Shiau, R. F. Schinazi and J. Walker	341
	9.1. Introduction	341
	9.2. 5-Iodo-2'-deoxyuridine	344
	9.3. Virus enhancement and induction	355
	9.4. 5-Iodo-2'-deoxycytidine (IdCyd)	358
	9.5. 5-Iodo-5'-amino-2',5'-dideoxyuridine and related amino-deoxyribo-	
	nucleosides	361
10.	AZAPYRIMIDINE NUCLEOSIDES B. RADA, Slovak Academy of Sciences, Bratislava, Czechoslovakia, and J. Doskočil, Czechoslovak Academy of Sciences, Prague, Czechoslovakia	385
	10.1. Introduction	386
	10.2. 6-Azauridine	387
	10.3. 5-Azacytidine 10.4. 3-Deazauridine	419
1.	ANTIVIRAL EFFECTS OF SINGLE-STRANDED POLYNUCLEO- TIDES AND THEIR MODE OF ACTION	437
	N. Stebbing, AMGen Inc., California, USA	437
	11.1. Introduction: The concept of strategic sequences	437
		440
	11.2. Candidate strategic sequences in animal virus genomes	
	11.3. Inhibition of lytic viruses by single-stranded RNAs	448
	11.4. Inhibition of reverse transcriptases by single-stranded RNAs 11.5. Alternative mechanisms of action of antiviral and antitumor	452
	polynucleotides	461

. 12.	CRITICAL REVIEW AND RISK EVALUATION OF PHOTO-	479
4	L. E. Bockstahler, Kiki B. Hellman, C. D. Lytle, Bureau of Radiological Health, Maryland, USA; T. P. Coohill, Western Kentucky University, USA;	
	12.1. Introduction systems 1	480
	12.2. Need for effective therapy months and the state of	480
	12.3. Basis for photodynamic therapy to has another to rouse fine A. V.	483
	12.4. Clinical photodynamic therapy to an allowing a samusonal 3.4.	491
	12.5. Potential adverse effects	493
	12.6. Conclusions and future prospects	497
	ARANGCEROSIDES AND ARANGCECTIDES IN VIR grammus .7.21	499
13.	IMMUNOPOTENTIATING SUBSTANCES WITH ANTIVIRAL	611
	G. H. Werner and A. Zerial, Rhone-Poulenc Recherches, France and A.	511
	13.1 7 . 1 .:	£11
	12.2 Immediate in cital infections	511
	12.2 Immunosotantiating substances of natural solicing	512
	12.4 1-1-6	521
	12.5 Cynthetic substances	533
	0.00	533
	13.6. Possible mechanisms of the antiviral activity of immunopotentiating a substances	543
	13.7. Possible therapeutic applications of immunopotentiating drugs with antiviral activity	545
	AND THE RAL REDINATED THROUGH TO SUPERING ULTED	0
INI	SIDES STODE 2 DECKYLIGIDINE STUDG 2 DECKYCYT DINEXAC	559
	SACODO-SEAMONO 2. FERIDEOXYURBDINE	
	W. H. PRUSSE, M. S. CHEN IN H. Harden T. S. LIN, W. R. MANCINI.	
	M. J. Jernson Y. Stanker E. J. Schimazijanski Placera.	
LIF	anibrary constraint	
	2.5. Schodo-Sisminucy, Sistudeoro unidine and related amino-daexy, illusing	
	AZONY REMONÉ NUCLEOSITES	
	B. Kada, Storch Bentemy of Sciences Britishnel, Lerchostorike 200	
	AN BYRAU EFFECTS OF SINGLESSIC SUPER FOLISSIC CO.	
	N Stephend & When Inc., Colympia, CSA	
	• III Introduction II - cencept of strategic sequences	
	11.1. Condictor statege sequitors in activate areas generates	
	1) S. Abergaine mechanisms of action of antivital and antitudor	
	p alvapeleoudes	

CHAPTER 1

THE NATURE AND CLASSIFICATION OF VIRUSES OF MAN

FRANK FENNER

John Curtin School of Medical Research, The Australian National University, Canberra, Australia

CONTENTS

1.1.	. Introductory remarks and address of the cold three relations of the control of	0TD: 1
1.2.	. Introduction in the control of the	
1.3.	. The nature of viruses	2
1.4.	. The chemical composition of animal viruses	2
1.5.	. The structure of animal viruses	5
1.6.	. The structure of animal viruses . Classification of viruses	7
1.7.	. Short descriptions of the major groups of DNA viruses of vertebrates	9
1.8.	. Short descriptions of the major groups of RNA viruses of vertebrates	14
1.9.	. Unclassified viruses	24
	Pafarances	24

1.1. INTRODUCTORY REMARKS

Studies on viral chemotherapy begin with experiments on virus-infected cultured cells, then move to viral infections in intact experimental animals, and finally, in the few cases where the earlier experiments are sufficiently promising, to clinical trials in man. The initial investigations are usually carried out with particular 'model' viruses that lend themselves to experimental manipulation. In order to appreciate the significance of discoveries made with such model systems it is necessary to understand how generally any discovered effect may extend among viruses pathogenic for man. This involves a knowledge of viral classification; if a chemotherapeutic effect is discovered which operates through its effect on a particular viral enzyme, for example, it can be expected to behave similarly in other viruses that possess that enzyme, but not in viruses of other families that do not.

This review begins with a description of the chemical composition and physical structure of the virions of the viruses that affect vertebrate animals. There follows a brief account of each of the twenty families of viruses that encompass almost all the viruses that affect man and other vertebrates.

1.2. INTRODUCTION

Virology began as a branch of pathology. At the end of the nineteenth century, when the microbial etiology of many infectious diseases had been established, pathologists recognized that there were a number of common infectious diseases of man and his domesticated animals for which neither a bacterium nor a protozoan could be incriminated as the causal agent. In 1898 Loeffler and Frosch demonstrated that foot-and-mouth disease could be transferred from one animal to another by material which could pass through a filter that retained the smallest bacteria. Following this discovery such diseases were tentatively ascribed to what were first called 'ultramicroscopic filterable viruses', then 'ultrafilterable viruses', and, ultimately, just 'viruses'. The word 'virus' itself, originally meaning a disease-producing

poison, was appropriated to this particular class of agents because of the currency that Jenner had given to the term in describing cowpox and smallpox viruses a hundred years earlier.

1.3. THE NATURE OF VIRUSES

Unicellular microorganisms can be arranged in order of decreasing size and complexity: protozoa, yeasts and certain fungi, bacteria, mycoplasmas, rickettsiae and chlamydiae. Then there is a major discontinuity, for in one sense the viruses cannot be regarded as microorganisms at all. True microorganisms, however small and simple, are cells. They always contain DNA as the repository of their genetic information, and they also have their own machinery for producing energy and macromolecules. Microorganisms grow by synthesizing their own macromolecular constituents (nucleic acid, protein, carbohydrate and lipid), and they multiply by binary fission.

Viruses, on the other hand, contain only one type of nucleic acid, which may be either DNA or RNA, double-stranded or single-stranded. Furthermore, since viruses have no ribosomes or other organelles, they are completely dependent upon their cellular hosts for the machinery of protein synthesis, energy production, and so on. Unlike any of the microorganisms, many viruses can, in suitable cells, reproduce themselves from a single nucleic acid molecule. The key differences between viruses and microorganisms are listed in Table 1.

TABLE 1. Properties of Microorganisms and Viruses*

	Growth on nonliving media	Binary fission	DNA and RNA	NG to equoty to NA to equoty to Ribosomes	Sensitivity to antibiotics	Sensitivity to interferon
Bacteria	+	+	+	+	+	_
Mycoplasmas	+	+	+	+	+	_
Rickettsiae		RESEARCE	vozt.ni	L BYTROD	+	_
Chlamydiae	_ 0.0	+	13/14/100	The state of	+	+
Viruses					alto co s te totio	1 to

^{*}From Fenner and White (1976). A stude istraction to the interior of a part as in

Viruses differ from cellular microorganisms in that they exist in two or sometimes three physically and functionally different states. Firstly, they exist as viral particles, or virions, which are the inert form that carries the viral genome from one host cell and/or one host organism to another one. Commonly, but incorrectly, the word 'virus' is often used as a synonym for 'virion'. The second functional state is 'vegetative virus', in which the viral genome undergoes replication, directs the formation of polypeptides and controls the assembly and often the release of progeny virions. In this state the 'virus' is part of the host cell that it infects; the unit is the virus-infected cell. Finally, with a few families of viruses, including lysogenic bacteriophages, papovaviruses and retroviruses, the viral genome, in whole or in part, is at times integrated into the host cell DNA as a 'provirus'. In the case of retroviruses, the provirus is a DNA copy of the RNA genome of the virion.

Virions consist of a genome of either DNA or RNA enclosed within a protective coat of virus-specified protein molecules, some of which may be associated with carbohydrates or lipids specified by the viral or more commonly the host cell genome. In the vegetative state and as 'provirus', viruses are reduced to their constituent genomes. The simplest 'viruses' (viroids) (Diener, 1979) may be transmitted from one host to another and exist only as naked molecules of nucleic acid, possibly associated with certain cellular components. At the other extreme, the virions of the larger animal viruses, e.g. the poxviruses and the retroviruses, have a relatively complex structure.

Viruses parasitize every kind of organism; possibly, indeed, every individual organism, prokaryote and eukaryote, is infected with one or more viruses. For our purposes we need consider only the viruses of vertebrate animals—mainly those of man, but also some viruses that infect domestic or experimental animals and are important in experimental virology, including viral chemotherapy.

1.4. THE CHEMICAL COMPOSITION OF ANIMAL VIRUSES GE 1-000.01

The virions of the simpler viruses consist solely of nucleic acid and a few virus-specified polypeptides. More complex viruses usually also contain lipids and carbohydrates; in the great majority of viral families these chemical components are not specified by the viral genome but are derived from the cells in which the viruses multiply. In exceptional situations, cellular nucleic acids or polypeptides may be incorporated in viral particles.

membrane protein" (see Fig. 1). ThadisA Siaus W. 1.1.1 of repeating units of one c

Viruses, unlike microorganisms, contain only a single species of nucleic acid, which may be DNA or RNA. In different families of viruses the nucleic acid is single- or double-stranded, a single molecule or several, and if a single molecule either linear or cyclic. About 20 per cent of the cytosine residues in the ranavirus FV3 are methylated, but neither 5-methyl cytosine nor novel bases of the type encountered in some bacterial viruses have been found in other vertebrate viral nucleic acids. However, the nucleic acids of some viruses contain oligonucleotides rich in adenylate, of unknown function. The base composition of DNA from animal viruses covers a far wider range than that of the vertebrates, for the guanine plus cytosine (G+C) content of different viruses varies from 35 to 74 per cent, compared with 40 to 44 per cent for all chordates. Indeed, the G+C content of the DNA of viruses of one family (Herpesviridae) ranges from 46 to 74 per cent.

The molecular weights of the DNAs of different animal viruses vary from 1.5 to 185 million; the range of molecular weights of viral RNAs is much less, from just over about 2.5 to 15 million. The nucleic acid can be extracted from viral particles with detergents or phenol. The released molecules are often easily degraded but if kept intact the isolated nucleic acid of viruses belonging to certain families is infectious. In other cases, the isolated nucleic acid is not infectious even though it contains all the necessary genetic information, for its transcription depends upon a virion-associated transcriptase without which multiplication cannot proceed.

The genomes of all DNA viruses consist of a single molecule of nucleic acid, but the genomes of many RNA viruses consist of several different molecules, which are probably loosely linked together in the virion. In viruses whose genome consists of single-stranded nucleic acid, the viral nucleic acid is either the 'positive' strand (in RNA viruses, equivalent to messenger RNA) or the 'negative' (complementary) strand. Preparations of some Parvoviridae, which have genomes of single-stranded DNA, consist of particles that contain either the positive or the complementary strand.

Viral preparations often contain some particles with an atypical content of nucleic acid. Host-cell DNA is found in some papovaviruses, and what appear to be cellular ribosomes in some arenaviruses. Several copies of the complete viral genome may be enclosed within a single particle (as in paramyxoviruses) or viral particles may be formed that contain no nucleic acid ('empty' particles) or that have an incomplete genome ('defective interfering' particles), lacking part of the nucleic acid that is needed for infectivity.

Terminal repetition occurs in the DNA of some vertebrate viruses and the genome of retroviruses consists of two or three identical single-stranded RNA molecules linked end to end, but most sequences are unique. The largest viral genomes contain several hundred genes, while the smallest carry only sufficient information to code for about three proteins.

1.4.2. PROTEINS

The major constituent of the virion is protein, whose primary role is to provide the viral nucleic acid with a protective coat. The protein shells of the simpler viruses consist of repeating protein subunits. Sometimes the capsid protein consists of only one sort of polypeptide; more commonly there are two or three different polypeptides in the protein shell. Often certain of these surface polypeptides have a special affinity for complementary 'receptors' present on the surface of susceptible cells. They also contain the antigenic determinants that are responsible for the production of protective antibodies by the infected animal. Viral polypeptides are quite large, with molecular weights in the range

10,000–150,000 daltons. The smaller polypeptides are often, but not always, internal; the larger ones often, but not always, external. There are no distinctive features about the amino acid composition of the structural polypeptides of the virion, except that those intimately associated with viral nucleic acid in the 'core' of some icosahedral viruses are often relatively rich in arginine.

Viral envelopes usually originate from the cellular plasma membrane from which the original cellular proteins have been totally displaced by viral peplomers and a viral "membrane protein" (see Fig. 1). The peplomers consist of repeating units of one or two glycoproteins, the polypeptide moiety of which is virus-specified while the carbohydrate is added by cellular transferases. In many but not all enveloped viruses, the inside of the viral envelope is lined by a viral protein called the membrane or matrix protein.




Fig. 1 Schematic diagrams of the structure of a simple non-enveloped virion with an icosahedral capsid (A) and an enveloped virion with a tubular nucleocapsid with helical symmetry (B). The capsids consist of merphological subunits called capsomers, which are in turn composed of structural subunits that consist of one or more chemical subunits (polypeptide chains). Many icosahedral viruses have a 'core' (not illustrated), which consists of protein(s) directly associated with the nucleic acid, inside the icosahedral capsid. In viruses of type B the envelope is a complex structure consisting of an inner virus-specified protein shell (membrane protein, made up of structural subunits), a lipid layer derived from cellular lipids, and one or more types of morphological subunits (pepiomers), each of which consists of one or more virus-specified glycoproteins (from Fenner and White, 1976).

Not all structural viral proteins are primary gene products, since in viruses of several families the viral mRNA is translated into a large polypeptide that is enzymatically cleaved to yield two or more smaller virion proteins. Cleavage is often one of the terminal events in the assembly of the virion and it can occur on the virion after most of the proteins are already in place.

Although most virion polypeptides have a structural role, some have enzymatic activity. Many viruses contain a few molecules of an internal protein that functions as a transcriptase, one of the two kinds of peplomers in the envelope of orthomyxoviruses has neuraminidase activity, and several other enzymes are found in the virions of the larger, more complex viruses.

In addition to polypeptides that occur as part of the virion, part of the viral genome codes for polypeptides that have a functional role during viral multiplication but are not incorporated into viral particles. Few of these 'nonstructural viral proteins' have been characterized.

1.4.3. LIPID AND CARBOHYDRATE

Lipids and to a large extent carbohydrates are usually found only in viral envelopes except in the virions of poxviruses and some iridoviruses, where they occur in the outer membrane as well as the envelope. The lipids of viral envelopes are characteristic of the cell of origin, though minor differences may be demonstrable. About 50-60 per cent of the lipid is phospholipid and most of the remainder (20-30 per cent) is cholesterol. Some of the viral carbohydrate occurs in the envelope as glycolipid characteristic of the cell of origin, but most of it is part of the glycoprotein peplomers that project from the viral envelope.

1.5. THE STRUCTURE OF ANIMAL VIRUSES

Three structural classes of viruses of vertebrates can be distinguished: isometric particles, which are usually 'naked' but in some families are enclosed within a lipoprotein envelope; long tubular nucleoprotein structures, always surrounded by a lipoprotein envelope; and in a few groups, a more complex structure.

1.5.1. TERMINOLOGY

Virion (plural, virions) is used as a synonym for 'virus particle'. The protein coat of an isometric particle, or the elongated protein tube of viruses with helical symmetry, is called the capsid (Fig. 1). It may be 'naked', or it may be enclosed within a lipoprotein envelope (peplos) which is derived from cellular membranes as the virus matures by budding. Where the capsids directly enclose the viral nucleic acid, as is usual with tubular capsids but less common with isometric capsids, the complex is called the nucleocapsid. With most isometric particles, and in all complex virions, the capsid encloses another protein structure containing the viral genome, called the core.


Capsids consist of repeating units of one or a small number of protein molecules. Three levels of complexity can be distinguished. Chemical units, the ultimate gene products, are single polypeptides that may themselves constitute the structural units, or several polypeptides may form homo- or heteropolymers which constitute structural units. The structural units, or groups of them, may be visualized in the electron micrographs as morphological units. Morphological units that form part of a capsid are called capsomers; those projecting from the envelope are the peplomers (sometimes called 'spikes', an unsatisfactory term since they are never pointed and may, indeed, have knob-shaped ends).

The chemical units are sometimes held together by disulfide bonds to form the structural units, hence the practice of using reducing agents in polyacrylamide gel electrophoresis when analyzing viral proteins to determine their constituent polypeptides. The structural units are held together to form the capsid by noncovalent bonds, which may be polar (salt and hydrogen bonds) or nonpolar (van der Waals and hydrophobic bonds). The capsids of some viruses are readily disrupted in molar calcium or sodium chloride, suggesting electrovalent bonds between the structural units; others are unaffected by salt and can only be disrupted by detergents, suggesting that they are hydrophobically bonded.

1.5.2. ISOMETRIC VIRUSES

The capsomers of isometric viruses are arranged with icosahedral symmetry, because the icosahedron is that polyhedron with cubic symmetry which, if constructed of identical subunits, would least distort the subunits or the bonds between them.

An icosahedron (Fig. 2) has twenty equilateral triangular faces, twelve vertices, where the corners of five triangles meet, and thirty edges, where the sides of adjacent pairs of triangles meet. It shows two-fold symmetry about an axis through the center of each edge (Fig. 2A), three-fold symmetry when rotated around an axis through the center of each triangular face (Fig. 2B), and five-fold symmetry about an axis through each vertex (Fig. 2C). Each triangular face may be thought of as containing, and being defined by, three asymmetric units (i.e. units that have no regular symmetry axes themselves) so that a minimum of sixty asymmetric units are required to construct an icosahedron.






Fig. 2. Features of icosahedral structure. Above: Regular icosahedron viewed along two-fold (A), three-fold (B), and five-fold (C) axes. Various clusterings of structural subunits give characteristic appearances of capsomers in electron micrographs. With T=3 the structural subunits may be arranged as 20T trimers (D), capsomers are then difficult to define, as in poliovirus; or they may be grouped as 12 pentamers and 20 hexamers (E) which form bulky capsomers as in *Parvovirus*, or as dimers on the faces and edges of the triangular facets (F), producing an appearance of a bulky capsomer on each face, as in *Calicivirus* (from Fenner and White, 1976).

The pattern seen on the surface of the virion need not reflect the way in which the structural units are bonded together, and gives no clue as to whether the structural units are constituted by single chemical units or are homo- or heteropolymers of the chemical units. However, the number of structural units in each capsomer can be guessed at from the arrangement and size of the capsomers (Fig. 2).

All animal viruses whose genome is DNA have isometric (or complex) capsids, as do those whose genome is double-stranded RNA (Reoviridae) and the viruses of two large families (Picornaviridae and Togaviridae) whose genome consists of a single molecule of single-stranded RNA.

The state of the s

Tubular nucleocapsids are found in many families of viruses of vertebrates, but only among those whose genome consists of single-stranded RNA. None of these occurs 'naked',